Under the new deal, financial terms of which were not announced, contract research organisation (CRO) will acquire all of fellow Montreal, Canada-based Vida’s equipment, intellectual properties and analytical methods.
A5 will also taken on all of Vida’s existing contract research customers.
Richard Azani, A5 CEO, said: "We are very pleased to begin the process of acquisition of these assets. Our strategic vision is to use the CRO assets to create a research based profit centre and to leverage that internal core competence to develop and commercialize novel biotechnology products."